In Thursday’s Wall Street session, TG Therapeutics Inc (NASDAQ:TGTX) shares traded at $37.37, down -2.48% from the previous session.
TGTX stock price is now -0.13% away from the 50-day moving average and 17.65% away from the 200-day moving average. The market capitalization of the company currently stands at $5.93B.
With the price target of $50, TD Cowen recently initiated with Buy rating for TG Therapeutics Inc (NASDAQ: TGTX). On August 02, 2023, Goldman Upgraded its previous ‘Sell’ rating to ‘Neutral’ on the stock reducing its target price from $16 to quote $12, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Power Sean A, CFO sold 11,337 shares of the company’s stock on Jan 03 ’25. The stock was sold for $343,443 at an average price of $30.29. Upon completion of the transaction, the CFO now directly owns 670,632 shares in the company, valued at $25.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06 ’25, CFO Power Sean A sold 10,021 shares of the business’s stock. A total of $285,939 was realized by selling the stock at an average price of $28.53. This leaves the insider owning 660,611 shares of the company worth $24.69 million. A total of 9.96% of the company’s stock is owned by insiders.
During the past 12 months, TG Therapeutics Inc has had a low of $16.21 and a high of $46.48. As of last week, the company has a debt-to-equity ratio of 1.07, a current ratio of 4.02, and a quick ratio of 3.04.
The net profit margin was 10.13% and return on equity was 19.70% for TGTX. For the current quarter, analysts expect TGTX to generate $147.76M in revenue.
